These results are consistent with those of two prior studies based on the UK primary care database and the Italian administrative database each, where an approximately 30% reduction in pneumonia risk with DPP-4 inhibitor use relative to other second-line oral glucose-lowering therapy has been reported5,42. This evidence concerns the gene DPP4 and susceptibility to pneumonia measurement.